Genticel S.A, Serum Institute of India deal

Genticel granted the institute exclusive rights to Vaxiclase technology in acellular multivalent combination vaccines to prevent Bordetella pertussis (whooping cough). The license covers all countries except the U.S., Australia, Canada, Israel, Japan, New Zealand, Turkey and the countries in greater Europe. Genticel is eligible for up to $57 million, comprising an upfront payment and development and sales milestones, plus single-digit royalties on net sales. The companies have an option to expand the deal to become worldwide. ...